{"id":95589,"date":"2026-05-22T18:22:53","date_gmt":"2026-05-22T12:52:53","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=95589"},"modified":"2026-05-22T18:22:54","modified_gmt":"2026-05-22T12:52:54","slug":"jubilant-pharmova-q4-fy26-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/","title":{"rendered":"Jubilant Pharmova Q4 FY26 Results: PAT Rs 119 Cr"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><strong><a href=\"https:\/\/univest.in\/user\/stocks\/jublpharm\/jubilant-pharmova-ltd-share-price-today\">Jubilant Pharmova<\/a> Q4 FY26<\/strong> results were declared on May 22, 2026. The company reported PAT of Rs 119 crore for the quarter ended March 31, 2026, down 21.0% YoY compared to Rs 151 crore in Q4 FY25. Revenue from operations was Rs 2,290 crore, up 18.0% YoY. Results are on a Consolidated basis. Jubilant Pharmova is a Pharmaceuticals and Contract Manufacturing company listed on Indian stock exchanges.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here \u2013 Get Free Investment Predictions<\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#Jubilant_Pharmova_Q4_FY26_Financial_Highlights\" title=\"Jubilant Pharmova Q4 FY26 Financial Highlights\">Jubilant Pharmova Q4 FY26 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#Jubilant_Pharmova_Q4_FY26_Performance_Analysis\" title=\"Jubilant Pharmova Q4 FY26 Performance Analysis\">Jubilant Pharmova Q4 FY26 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#Key_Factors_Driving_Jubilant_Pharmova_Q4_FY26_Results\" title=\"Key Factors Driving Jubilant Pharmova Q4 FY26 Results\">Key Factors Driving Jubilant Pharmova Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#Revenue_Performance\" title=\"Revenue Performance\">Revenue Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#Profitability_and_Margin_Analysis\" title=\"Profitability and Margin Analysis\">Profitability and Margin Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#Sector_Tailwinds_and_India_Macro_Environment\" title=\"Sector Tailwinds and India Macro Environment\">Sector Tailwinds and India Macro Environment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#FY27_Outlook\" title=\"FY27 Outlook\">FY27 Outlook<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#Frequently_Asked_Questions_on_the_company\" title=\"Frequently Asked Questions on the company\">Frequently Asked Questions on the company<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#What_is_Jubilant_Pharmova_Q4_FY26_net_profit\" title=\"What is Jubilant Pharmova Q4 FY26 net profit?\">What is Jubilant Pharmova Q4 FY26 net profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#What_is_Jubilant_Pharmova_Q4_FY26_revenue\" title=\"What is Jubilant Pharmova Q4 FY26 revenue?\">What is Jubilant Pharmova Q4 FY26 revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#When_were_Jubilant_Pharmova_Q4_FY26_results_declared\" title=\"When were Jubilant Pharmova Q4 FY26 results declared?\">When were Jubilant Pharmova Q4 FY26 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-fy26-results\/#Is_Jubilant_Pharmova_a_good_investment_after_Q4_FY26_results\" title=\"Is Jubilant Pharmova a good investment after Q4 FY26 results?\">Is Jubilant Pharmova a good investment after Q4 FY26 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Jubilant_Pharmova_Q4_FY26_Financial_Highlights\"><\/span><strong>Jubilant Pharmova Q4 FY26 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26 (Rs Cr)<\/th>\n<th>Q4 FY25 (Rs Cr)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<tr>\n<td><strong>Revenue<\/strong><\/td>\n<td>Rs 2,290 crore<\/td>\n<td>Rs 1,929 crore<\/td>\n<td>+18.0%<\/td>\n<\/tr>\n<tr>\n<td><strong>Gross Profit<\/strong><\/td>\n<td>Rs 223 crore<\/td>\n<td>Rs 250 crore<\/td>\n<td>-10.0%<\/td>\n<\/tr>\n<tr>\n<td><strong>Net Profit<\/strong><\/td>\n<td>119<\/td>\n<td>151<\/td>\n<td>-21.0%<\/td>\n<\/tr>\n<tr>\n<td><strong>Basis<\/strong><\/td>\n<td colspan=\"3\">Consolidated<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Note: Jubilant Pharmova Q4 FY26 results declared May 22, 2026. Verify from BSE\/NSE audited filings before investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jubilant_Pharmova_Q4_FY26_Performance_Analysis\"><\/span><strong>Jubilant Pharmova Q4 FY26 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Jubilant Pharmova Q4 FY26<\/strong> results reflect the company&#8217;s operational performance during the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Jubilant Pharmova operates in the Pharmaceuticals and Contract Manufacturing sector, which is supported by India&#8217;s GDP growth above 6.5% and domestic demand tailwinds in FY26.<\/p>\n<p>Revenue of Rs 2,290 crore was up 18.0% YoY. Strong revenue growth reflects market share gains and healthy demand.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\">Screen the best stocks on the Univest Screener.<\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_Driving_Jubilant_Pharmova_Q4_FY26_Results\"><\/span><strong>Key Factors Driving Jubilant Pharmova Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Performance\"><\/span><strong>Revenue Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue of Rs 2,290 crore in Jubilant Pharmova Q4 FY26 was up 18.0% YoY. The double-digit topline growth reflects strong end-market demand, market share gains, and favourable pricing conditions in the Pharmaceuticals and Contract Manufacturing sector. The January to March 2026 quarter is the year-end quarter, characterised by strong order execution and fiscal year-end activity across Indian corporates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Profitability_and_Margin_Analysis\"><\/span><strong>Profitability and Margin Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Jubilant Pharmova Q4 FY26 PAT of Rs 119 crore down 21.0% YoY. Stable profitability reflects consistent margin management.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Sector_Tailwinds_and_India_Macro_Environment\"><\/span><strong>Sector Tailwinds and India Macro Environment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Pharmaceuticals and Contract Manufacturing sector saw constructive operating conditions in Q4 FY26. India&#8217;s macroeconomic environment, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption, supported demand across sectors. The Reserve Bank of India&#8217;s accommodative liquidity stance aided credit conditions. For Jubilant Pharmova, these macro and sectoral tailwinds provided a supportive backdrop in the January to March 2026 quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Outlook\"><\/span><strong>FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Following the firm results, management commentary on FY27 revenue guidance, margin trajectory, capex plans, and demand pipeline will be the key investor focus areas. The Pharmaceuticals and Contract Manufacturing sector benefits from India&#8217;s long-term growth story including urbanisation, infrastructure investment, and rising middle-class consumption. Consistent growth delivery and margin improvement remain the management&#8217;s strategic priorities.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_the_company\"><\/span><strong>Frequently Asked Questions on the company<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div>\n<div>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Jubilant_Pharmova_Q4_FY26_net_profit\"><\/span><strong>What is Jubilant Pharmova Q4 FY26 net profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div>\n<p><strong>Ans.<\/strong> <strong>Jubilant Pharmova Q4 FY26<\/strong> PAT of Rs 119 crore, down 21.0% YoY from Rs 151 crore in Q4 FY25. Results declared May 22, 2026, on a Consolidated basis. Verify from BSE\/NSE audited filings.<\/p>\n<\/div>\n<\/div>\n<div>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Jubilant_Pharmova_Q4_FY26_revenue\"><\/span><strong>What is Jubilant Pharmova Q4 FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div>\n<p><strong>Ans.<\/strong> Jubilant Pharmova Q4 FY26 revenue from operations was Rs 2,290 crore, up 18.0% YoY. Verify complete financials from BSE\/NSE filings.<\/p>\n<\/div>\n<\/div>\n<div>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Jubilant_Pharmova_Q4_FY26_results_declared\"><\/span><strong>When were Jubilant Pharmova Q4 FY26 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div>\n<p><strong>Ans.<\/strong> Jubilant Pharmova Q4 FY26 results were declared on May 22, 2026, at the board of directors meeting approving audited Q4 and full-year FY26 financial statements.<\/p>\n<\/div>\n<\/div>\n<div>\n<h3><span class=\"ez-toc-section\" id=\"Is_Jubilant_Pharmova_a_good_investment_after_Q4_FY26_results\"><\/span><strong>Is Jubilant Pharmova a good investment after Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<div>\n<p><strong>Ans.<\/strong> Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before investing in Jubilant Pharmova.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE\/NSE filings. Consult a SEBI-registered financial advisor.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jubilant Pharmova Q4 FY26 results May 22 2026. PAT of Rs 119 crore down 21.0% YoY. Revenue Rs 2,290 crore. Analysis.<\/p>\n","protected":false},"author":26,"featured_media":95636,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-95589","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779454386:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_focus_keyword":["Jubilant Pharmova Q4"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Jubilant Pharmova Q4 FY26 Results: PAT Rs 119 Cr"],"rank_math_description":["Jubilant Pharmova Q4 FY26 results May 22 2026. PAT of Rs 119 crore down 21.0% YoY. Revenue Rs 2,290 crore. Analysis."],"_thumbnail_id":["95636"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["13135"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/05\/Jubilant-Pharmova-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/95589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=95589"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/95589\/revisions"}],"predecessor-version":[{"id":95637,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/95589\/revisions\/95637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/95636"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=95589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=95589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=95589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}